APLMW (Apollomics) DeferredTaxAndRevenue: $0.00 Mil (As of Dec. 2025)


APLMW Apollomics Inc APLMW
31 GF Score
Price $0.01
! 4 Warning Signs
View Full Analysis

What is Apollomics DeferredTaxAndRevenue?

Apollomics APLMW -2.16% 31 DeferredTaxAndRevenue is $0.00 Mil as of Dec. 2025. GuruFocus rates APLMW with a GF Score™ of 31/100. The stock has 4 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Apollomics's current deferred tax and revenue for the quarter that ended in Dec. 2025 was $0.00 Mil.

Apollomics DeferredTaxAndRevenue Related Terms

Apollomics DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Apollomics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollomics DeferredTaxAndRevenue Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
APLMW
31GF Score
Apollomics Inc APLMW
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.00 Mil mean?
Apollomics (APLMW) has a DeferredTaxAndRevenue of $0.00 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Apollomics.
Is Apollomics' DeferredTaxAndRevenue too high?
Apollomics' current DeferredTaxAndRevenue is $0.00 Mil. Overall, Apollomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Apollomics' DeferredTaxAndRevenue compare to HYPD and MGX?
Apollomics' DeferredTaxAndRevenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Apollomics. Apollomics's current DeferredTaxAndRevenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollomics stock overvalued right now?
Apollomics (APLMW) has a current DeferredTaxAndRevenue of $0.00 Mil. The current DeferredTaxAndRevenue is $0.00 Mil. Apollomics' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Apollomics (APLMW), the current DeferredTaxAndRevenue is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apollomics Business Description

Other Exchanges APLM:USA
Address 989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
31GF Score

Get the complete analysis for APLMW

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price